Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Recursion (NASDAQ: RXRX) has strengthened its Board of Directors with two significant appointments effective March 15th. Dr. Namandjé Bumpus, former FDA Principal Deputy Commissioner until December 2024, brings extensive experience in regulatory science and AI integration. Elaine Sun, current COO and CFO at Mammoth Biosciences, contributes 30 years of life sciences and financial industry expertise.
Dr. Bumpus previously served as FDA's Chief Scientist and was instrumental in shaping the agency's strategic direction, particularly in AI regulatory science integration. She also held positions at Johns Hopkins University School of Medicine as an endowed professor and department chair.
Elaine Sun's experience includes leadership roles at Halozyme Therapeutics and SutroVax (now Vaxcyte), along with advisory roles in M&A and financing transactions exceeding $50 billion at Evercore Partners and Merrill Lynch. She currently serves on the boards of Dynavax Technologies and Asher Biotherapeutics.
Recursion (NASDAQ: RXRX) ha rafforzato il suo Consiglio di Amministrazione con due importanti nomine a partire dal 15 marzo. Dr. Namandjé Bumpus, ex Commissario Principale Aggiunto della FDA fino a dicembre 2024, porta con sé una vasta esperienza nella scienza regolatoria e nell'integrazione dell'IA. Elaine Sun, attuale COO e CFO di Mammoth Biosciences, contribuisce con 30 anni di esperienza nelle scienze della vita e nel settore finanziario.
Il Dr. Bumpus ha precedentemente ricoperto il ruolo di Chief Scientist della FDA ed è stata fondamentale nel definire la direzione strategica dell'agenzia, in particolare nell'integrazione della scienza regolatoria dell'IA. Ha anche ricoperto posizioni presso la Johns Hopkins University School of Medicine come professore ordinario e capo dipartimento.
L'esperienza di Elaine Sun include ruoli di leadership presso Halozyme Therapeutics e SutroVax (ora Vaxcyte), insieme a ruoli di consulenza in operazioni di M&A e finanziamento superiori a 50 miliardi di dollari presso Evercore Partners e Merrill Lynch. Attualmente fa parte dei consigli di amministrazione di Dynavax Technologies e Asher Biotherapeutics.
Recursion (NASDAQ: RXRX) ha fortalecido su Junta Directiva con dos nombramientos significativos a partir del 15 de marzo. Dr. Namandjé Bumpus, ex Comisionado Principal Adjunto de la FDA hasta diciembre de 2024, aporta una amplia experiencia en ciencia regulatoria e integración de IA. Elaine Sun, actual COO y CFO de Mammoth Biosciences, contribuye con 30 años de experiencia en ciencias de la vida y en la industria financiera.
El Dr. Bumpus anteriormente se desempeñó como Científico Jefe de la FDA y fue fundamental en la definición de la dirección estratégica de la agencia, especialmente en la integración de la ciencia regulatoria de IA. También ocupó cargos en la Escuela de Medicina de la Universidad Johns Hopkins como profesor titular y jefe de departamento.
La experiencia de Elaine Sun incluye roles de liderazgo en Halozyme Therapeutics y SutroVax (ahora Vaxcyte), junto con roles de asesoría en transacciones de M&A y financiamiento que superan los 50 mil millones de dólares en Evercore Partners y Merrill Lynch. Actualmente forma parte de las juntas de Dynavax Technologies y Asher Biotherapeutics.
Recursion (NASDAQ: RXRX)는 3월 15일부터 두 명의 중요한 인사를 이사회에 임명하여 강화했습니다. Dr. Namandjé Bumpus는 2024년 12월까지 FDA의 부국장직을 맡았으며, 규제 과학 및 AI 통합에 대한 폭넓은 경험을 가지고 있습니다. Elaine Sun은 Mammoth Biosciences의 COO이자 CFO로 30년의 생명과학 및 금융 산업 경험을 제공합니다.
Bumpus 박사는 이전에 FDA의 수석 과학자로 재직하며 기관의 전략적 방향을 설정하는 데 중요한 역할을 했으며, 특히 AI 규제 과학 통합에 기여했습니다. 또한 Johns Hopkins University School of Medicine에서 석좌 교수 및 학과장을 역임했습니다.
Elaine Sun의 경험에는 Halozyme Therapeutics와 SutroVax(현재 Vaxcyte)에서의 리더십 역할이 포함되며, Evercore Partners와 Merrill Lynch에서 500억 달러를 초과하는 M&A 및 자금 조달 거래에 대한 자문 역할도 수행했습니다. 현재 그녀는 Dynavax Technologies와 Asher Biotherapeutics의 이사회에서 활동하고 있습니다.
Recursion (NASDAQ: RXRX) a renforcé son Conseil d'Administration avec deux nominations significatives à compter du 15 mars. Dr. Namandjé Bumpus, ancienne Commissaire Principale Adjointe de la FDA jusqu'en décembre 2024, apporte une vaste expérience en science réglementaire et en intégration de l'IA. Elaine Sun, actuelle COO et CFO de Mammoth Biosciences, contribue avec 30 ans d'expérience dans les sciences de la vie et l'industrie financière.
Le Dr. Bumpus a précédemment été Scientifique en Chef de la FDA et a joué un rôle clé dans l'orientation stratégique de l'agence, notamment dans l'intégration de la science réglementaire de l'IA. Elle a également occupé des postes à la Johns Hopkins University School of Medicine en tant que professeur titulaire et chef de département.
L'expérience d'Elaine Sun comprend des rôles de leadership chez Halozyme Therapeutics et SutroVax (maintenant Vaxcyte), ainsi que des rôles de conseil dans des transactions de M&A et de financement dépassant 50 milliards de dollars chez Evercore Partners et Merrill Lynch. Elle siège actuellement aux conseils d'administration de Dynavax Technologies et d'Asher Biotherapeutics.
Recursion (NASDAQ: RXRX) hat seinen Vorstand mit zwei bedeutenden Ernennungen zum 15. März verstärkt. Dr. Namandjé Bumpus, ehemalige stellvertretende Kommissarin der FDA bis Dezember 2024, bringt umfangreiche Erfahrung in der regulatorischen Wissenschaft und der Integration von KI mit. Elaine Sun, derzeit COO und CFO von Mammoth Biosciences, hat 30 Jahre Erfahrung in den Lebenswissenschaften und der Finanzbranche.
Dr. Bumpus war zuvor Chief Scientist der FDA und spielte eine entscheidende Rolle bei der Gestaltung der strategischen Ausrichtung der Agentur, insbesondere bei der Integration der KI-regulatorischen Wissenschaft. Sie hatte auch Positionen an der Johns Hopkins University School of Medicine als ordentliche Professorin und Abteilungsleiterin inne.
Elaine Suns Erfahrung umfasst Führungspositionen bei Halozyme Therapeutics und SutroVax (jetzt Vaxcyte) sowie beratende Tätigkeiten in M&A- und Finanzierungstransaktionen, die 50 Milliarden Dollar übersteigen, bei Evercore Partners und Merrill Lynch. Derzeit ist sie Mitglied der Vorstände von Dynavax Technologies und Asher Biotherapeutics.
- Addition of former FDA Principal Deputy Commissioner strengthens regulatory expertise and AI strategy
- New board member brings M&A and financing expertise from transactions worth over $50 billion
- Enhanced leadership depth in clinical development and financial strategy
- None.
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.
Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th.
“I am delighted to welcome Elaine and Namandjé to Recursion’s Board,” said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. “As the company continues to grow its clinical pipeline and enhance its platform, our new Board members’ scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success.”
Dr. Namandjé N. Bumpus served as the FDA’s Principal Deputy Commissioner until December 31, 2024, after joining the agency in August 2022 as Chief Scientist. As Principal Deputy Commissioner she played a pivotal role in shaping the agency’s strategic direction and driving its day-to-day operations. She worked closely with the FDA Commissioner to spearhead key public health initiatives, strengthening regulatory frameworks, modernizing enterprise systems, and enhancing laboratory testing capabilities. She was also one of the foremost drivers of strategy for integration of AI into regulatory science at the agency. Prior to the FDA, Dr. Bumpus was an endowed professor and chair of the Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, where she also served as an associate dean. She earned a Ph.D. in pharmacology from the University of Michigan and completed a postdoctoral fellowship at The Scripps Research Institute. Her prior research has spanned across drug metabolism, drug-induced toxicity, mass spectrometry, and infectious disease pharmacology. Dr. Bumpus has received several honors, including the Presidential Early Career Award, the John J. Abel Award, and the Leon I. Goldberg Award, and is a fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine.
"I’m proud to join Recursion’s Board and contribute to its innovative approach to drug discovery and development,” said Dr. Bumpus, “I look forward to bringing the full scope of my experience as a scientist and a leader to help guide the company’s scientific approach and advance its impact on patients’ lives."
Elaine Sun is a 30-year life sciences and financial industry veteran with a track record of building and creating value for early- to late-stage biopharmaceutical companies. She is currently the Chief Operating Officer and Chief Financial Officer at Mammoth Biosciences, an in vivo gene editing therapeutics company co-founded by Nobel laureate and CRISPR pioneer Jennifer Doudna. She previously was SVP and CFO at Halozyme Therapeutics, a commercial-stage biotechnology company, and served as CFO and Chief Strategy Officer at SutroVax (now Vaxcyte), a developer of innovative vaccines. Earlier in her career, she advised pharmaceutical, biotechnology and medical device companies on M&A and financing transactions valued in excess of
"I am excited to support Recursion’s commitment to merging rigorous science with cutting-edge technology to accelerate drug discovery and development and reshape the industry,” said Ms. Sun, “It is truly inspiring, and I look forward to helping Recursion scale its impact and bring new, life-changing therapies to the market."
Rob Hershberg, MD/Ph.D., Recursion’s Chairman, added: “I am delighted to have such phenomenal additions to our Board at such an exciting time for Recursion. I speak for the entire Board when I say we are thrilled to strengthen the company's strategic leadership with these outstanding additions. Welcome Namandjé and Elaine!”
To learn more about Recursion’s Board of Directors, please visit: https://www.recursion.com/team
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Media Contact: Media@Recursion.com
Investor Contact: Investor@Recursion.com
Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s growth; Recursion’s leadership of the TechBio space; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2023. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Recursion media@recursion.com
FAQ
What strategic value do the new board members bring to Recursion (RXRX)?
When did Dr. Namandjé Bumpus join Recursion's board and what was her previous role?
What is Elaine Sun's current position outside of Recursion's board?
How will these appointments impact Recursion's (RXRX) clinical development strategy?
